In This Section
Investor Relations
Get stock updates, FAQs, and more.
Our Best-in-Class Companies
Find a powerful partner that promises results.
Contact Information
If you are representing a media outlet and have immediate questions, please contact:
MARCIA FREDERICK
614.543.6281
mfrederick@inventivhealth.com
Press Releases
inVentiv Clinical Solutions Expands its Global Alliance With Partnerships in Europe, Asia and Africa
Alliance Enhances Global Coverage and Deepens Capabilities
HOUSTON, TX, May 24, 2010 - inVentiv Clinical, a division of inVentiv Health (NASDAQ: VTIV), today announced a substantive expansion of the inVentiv Clinical Global Alliance with the additions of Protech Pharmaservices Corporation (PPC), Ecron Acunova and RDDA. These partners, along with ActivaCRO, will broaden inVentiv Clinical Solutions' clinical research capabilities in Latin America, Asia, Europe and Africa and provide CRO service coverage in more than 50 countries.
PPC (www.ppccro.com) is inVentiv Clinical’s Asia Pacific partner with its headquarters located in Taiwan. With vast clinical experience across Asia, PPC is renowned in major countries of clinical interest such as Taiwan, Japan, China, Korea, Hong Kong, Singapore, Malaysia and Australia. PPC is dedicated to serving the pharmaceutical, biotechnology, generic drug and medical device industries with a full spectrum of drug development solutions, including phase I - IV clinical study management, bioavailability / bioequivalence studies, central laboratory, data management and statistical analysis.
Ecron Acunova (www.ecronacunova.com ), inVentiv Clinical's partner for Europe, has its European headquarters in Frankfurt, Germany and operations across Europe, Asia and the Americas. With 23 years of clinical expertise, Ecron Acunova provides end-to-end services for phase I - IV clinical research, including clinical trial management, clinical data management, PK/PD services and central lab for pharmaceutical, biotech, nutritional, medical diagnostic and device sponsors. Ecron Acunova has existing relationships with several members of the Global Alliance, including an ongoing collaboration with Essential CRO, which was acquired by inVentiv Clinical early 2010, and a prior partnership with PPC in Taiwan.
RDDA (www.rddacro.co.za), inVentiv Clinical's African partner, is a contract research organization based in Pretoria, South Africa and was founded by three partners with a vision to provide the international pharmaceutical industry with expert services in clinical trials in Africa. RDDA provides regulatory, project management and monitoring support across Africa including South Africa, Namibia, Botswana, Zambia, Kenya, Mozambique and Zimbabwe.
“We are very pleased to welcome PPC, Ecron Acunova and RDDA to the inVentiv Clinical Global Alliance, which already includes ActivaCRO in Latin America (http://www.activa-cro.com). The expansion of our alliance is consistent with our mission to help clients accelerate quality clinical research in a cost-effective manner,” comments Michael Hlinak, President and CEO of inVentiv Clinical. “By forging alliances with these first-class partners, we are better positioned to provide our clients the unique, flexible solutions and unmatched quality they have come to expect from inVentiv Clinical, but on a global scale where it is needed today. Furthermore, this Global Alliance represents significant operational integration and access to rapidly developing clinical research markets.”
“We are pleased to offer our delivery capabilities in Western and Eastern European countries, including Ukraine and Russia, and to the partners in the inVentiv Clinical network,” said D A Prasanna, Founder and Vice Chairman of Ecron Acunova.
“PPC is glad to be part of a network that represents global integration and world-class solutions,” said Johnny Cheng, PPC Chief Operations Officer.
“We at RDDA are indeed very proud to be part of this prominent partnership which now covers the entire world. It is a great achievement for RDDA to be the sole and exclusive partner in Southern Africa. Apart from our in-depth therapeutic knowledge in oncology, haematology, HIV/AIDS, cardiovascular disorders, etc. where we have more than 10 years experience, we are committed through our partnership to widen our expertise to be a real and effective asset to the group,” Dr. Patrice Bassompierre, CEO of RDDA, said.
“We are delighted to welcome such recognized organizations to the partnership. With their incorporation, the inVentiv Clinical Global Alliance is presently in a position to cover the world´s major research locations,” said Mario Boskis, President and Chief Operating Officer of ActivaCRO.
To learn more about the inVentiv Clinical Global Alliance, please contact Fernando Martinez at fmartinez@inventivclinical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing; and our inability to determine the actual time at which the liquidation of the Columbia Strategic Cash Portfolio will be completed or the total losses that we will actually realize from that investment vehicle. . Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
